Development of iPS cells for various
types of regenerative medicine

In Japan, Europe and the United States, clinical trials (includes administration to humans) using iPS cells have begun. A future in which diseases that were once untreatable can be cured by regenerative medicine using iPS cells is beginning to become a reality.

Avoid risk of rejection

Transplantation or treatment using the individual’s own cells (autologous transplantation) is less likely to cause rejection.
It is believed that the availability of autologous transplantation therapy will eliminate the need to search for donors for various diseases and treatments can be initiated quickly.

Derivation of iPS cells from unneeded
teeth or urine

Our technology makes the derivation of iPS cells easy and suitable for anyone. Cells are collected from unneeded teeth (e.g. lost babey teeth) or urine.
Note: Tooth extraction for the sole purpose of producing iPS cells is not available (performed).

iPS cells for regenerative medicine

Our iPS cells are produced by the “RNA reprogramming method”, which is a state-of-the-art technology most suitable for clinical use without any alteration to the cell’s DNA.

iPS stocks are stored at two locations
in Japan and the U.S.

Personal iPS cells are safely stored even in the unlikely event of a power cut or natural disaster. The cells are expanded to create enough cells to allow storage at two secure locations in Japan and the U.S.

Leading company of iPS cells

Since our establishment in 2003, we have been engaged in cutting-edge research and development of iPS cells. Our cell culture media has been used in the research of Professor Yamanaka, a Nobel Prize winner. Our products are highly trusted both in Japan and overseas and have been cited in more than 6,000 papers to date. (As of November 2020)